Precision BioSciences Inc reports results for the quarter ended June 30 - Earnings Summary

• Precision BioSciences Inc DTIL.OQ reported a quarterly adjusted loss of $2.13​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $4.67. The mean expectation of four analysts for the quarter was for a loss of $1.57 per share. Wall Street expected results to range from $-2.31 to -9 cents per share.

• Revenue fell 100% to $18.00 thousand from a year ago; analysts expected $6.27 million.

• Precision BioSciences Inc's reported EPS for the quarter was a loss of $2.13​.

• The company reported a quarterly loss of $23.52 million.

• Precision BioSciences Inc shares had risen by 14.5% this quarter and gained 26.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.7% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Precision BioSciences Inc is $21.50, about 77.6% above its last closing price of $4.81

This summary was machine generated from LSEG data August 7 at 06:46 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)